Company Overview
Company Type: Public Company
Website: www.bionxt.com
Number of Employees: -
Ticker: BNXT (CNSX)
Year Founded: 2017


Business Description
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, the United States, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.4
Market Capitalization
32.2
TEV/Total Revenue
86.0x
EBITDA
(6.8)
Total Enterprise Value
36.5
TEV/EBITDA
NM
EBIT
(6.9)
Cash & ST Invst.
0.3
P/Diluted EPS Before Extra
NM
Net Income
(13.1)
Total Debt
4.7
Price/Tang BV
NM
Capital Expenditure
(0.1)
Total Assets
1.7
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Rogers, Hugh A. D.
President, CEO & Director
Meagher, Patrick Joseph
CFO & Director
Beckert, Thomas 
Managing Director of XP Diagnostics GmbH & Vektor Pharma TF GmbH
Jehle, Heinrich 
Head of Diagnostic Research
Sahr, Florian A.
Head of Project Management

Key Board Members
Name
Title
Rogers, Hugh A. D.
President, CEO & Director
Meagher, Patrick Joseph
CFO & Director
Lobenberg, Raimar 
Independent Director
Probst, Wolfgang 
Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
1820 Fir Street Suite 270 | Vancouver, BC | V6J 3B1 | Canada
Phone: 780 818 6422   

Current and Pending Investors
PharmaCielo Ltd. (TSXV:PCLO)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.31
Market Cap (mm)
32.2
Open
 0.31
Shares Out. (mm)
103.9
Previous Close
 0.31
Float %
93.4%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(3.1)%
Dividend Yield %
-
Day High/Low
 0.31/ 0.31
Diluted EPS Excl. Extra Items
(0.14)
52 wk High/Low
 0.85/ 0.31
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0020
Avg 3M Dly Vlm (mm)
0.01
Beta 5Y
0.11


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)
CNSX:BNXT - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
3a-diagnostics GmbH (Pending)
3a-diagnostics GmbH engages in the development, production, and marketing of point-of-care test systems. It also develops a pipeline of peptide-based biosensor screening tests for bacterial and viral infectious diseases which include stomatitis, periimplantitis, periodontitis, scarlet fever, and influenza. The company was incorporated in 2019 and is based in Frickenhausen, Germany.

Europe
Health Care Equipment
11.00
-
-
Vektor Pharma TF GmbH
Vektor Pharma TF GmbH develops and manufactures transdermal formulations and other drug loaded films. The company was founded in 2009 and is headquartered in Uttenweiler, Germany. As of September 13, 2019, Vektor Pharma TF GmbH operates as a subsidiary of XPhyto Therapeutics Corp.

Europe
Pharmaceuticals
-
-
-
Bunker Biopharma GmbH
Bunker Biopharma GmbH produces medicinal cannabis. The company was formerly known as SCUR-Alpha 998 GmbH and changed its name to Bunker Biopharma GmbH in November 2018. Bunker Biopharma GmbH was incorporated in 2018 and is based in Memmingerberg, Germany. As of November 14, 2018, Bunker Biopharma operates as a subsidiary of XPhyto Therapeutics Corp.

Europe
Pharmaceuticals
-
-
-
BUNKER Pflanzenextrakte GmbH
As of December 12, 2018, BUNKER Pflanzenextrakte GmbH operates as a subsidiary of Xphyto Therapeutics Corp.

Europe
Agricultural Products and Services
-
-
-
State-of-the-art coating and cutting equipment in Baden-WÃ¼rttemberg, Germany

Europe
-
-
-
-
XPhyto Laboratories Inc

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Aug-05-2023
-
Private Placement
Target
BioNxt Solutions Inc. (CNSX:BNXT)


2.98
Mar-10-2023
Mar-27-2023
Private Placement
Target
BioNxt Solutions Inc. (CNSX:BNXT)


1.48
Nov-29-2022
Dec-07-2022
Private Placement
Target
BioNxt Solutions Inc. (CNSX:BNXT)


2.06
Jul-22-2022
Sep-02-2022
Private Placement
Target
XPhyto Therapeutics Corp. (nka:BioNxt Solutions Inc. (CNSX:BNXT))


2.75
Mar-25-2022
Apr-22-2022
Private Placement
Target
XPhyto Therapeutics Corp. (nka:BioNxt Solutions Inc. (CNSX:BNXT))


1.81
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-03-2023
Executive/Board Changes - Other
BioNxt Solutions Inc. Announces Change of Directors
Aug-05-2023
Private Placements
BioNxt Solutions Inc. announced that it expects to receive CAD 3.975 million in funding
Aug-02-2023
Client Announcements
BioNxt Solutions Inc. Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease
May-15-2023
Product-Related Announcements
Bionxt Solutions Inc. Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease
May-10-2023
Company Conference Presentations
BioNxt Solutions Inc. Presents at International Investment Forum, May-10-2023 07:00 PM

M&A Advisors
Canaccord Genuity Corp.


Advisors
Most Recent Auditor
Davidson & Company LLP
M&A Advisors
Canaccord Genuity Corp.


Most Recent Auditor
Davidson & Company


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Wright Investors' Service Inc.

May 24, 2023 01:46 AM
BNXT
Flow of Funds Report for BioNxt Solutions Inc - prepared by Wright Investors Service
Notes
69
Zacks Small-Cap Research
Marin, Marla
Dec 23, 2021 05:00 AM
BNXT
Anticipated Benefits of 3a-Diagnostics Acquisition, Upcoming Clinical Trials & Recent Financings
Reports
15
Zacks Small-Cap Research
Marin, Marla
Sep 28, 2021 06:00 AM
BNXT
Leveraging an Extensive Portfolio, Including a Recently Launched COVID Test
Reports
17


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Lobenberg, Raimar 

5,000,000

4.81

1.6

Sep-09-2022


Probst, Wolfgang 

1,102,500

1.06

0.4

Apr-04-2023


Rogers B.Sc., LL.B, Hugh A. D.

711,500

0.68

0.2

Apr-04-2023


Meagher C.A., C.P.A., Patrick Joseph

26,000

0.03

0.0

Apr-03-2023



 


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Cannabis (Future), CBD Oral Strips (Future), Consultancy Services, RT-PCR Test System, Sale Of Test Kits


Upcoming Events
Date/Time
Type
Nov-02-2023
Annual General Meeting
Nov-28-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
-
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
News Releases
166 KB
Sep-29-2023
-
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
News Releases
196 KB
Sep-01-2023
-
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
Notice of the Meeting and Record Date
313 KB
Aug-28-2023
-
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
News Releases
204 KB
Aug-28-2023
Jun-30-2023
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
Interim Financial Statements
475 KB
Aug-08-2023
-
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
News Releases
220 KB
Aug-02-2023
-
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
News Releases
172 KB
May-29-2023
Mar-31-2023
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
Interim Financial Statements
471 KB
May-23-2023
Dec-31-2022
BioNxt Solutions Inc. (CNSX:BNXT)
SEDAR
Statement of Executive Compensation
172 KB
May-15-2023
-
BioNxt Solutions Inc. (CNSX:BNXT)
RNS
Non Regulatory Announcement
10 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Rogers B.Sc., LL.B, Hugh A. D. (President, CEO & Director)
Mar-16-2022
Common Shares
364,000
196,229
Derivative Exercise and Retained Stock
104.75
Multiple
Rogers B.Sc., LL.B, Hugh A. D. (President, CEO & Director)
Mar-14-2022
Common Shares
(177,500)
(198,219)
Open Market Disposition
(33.81)
Multiple
-
Mar-14-2022
Common Shares
(75,000)
(82,356)
Open Market Disposition
-
Exchange Announcement
-
Mar-14-2022
Common Shares
(102,500)
(115,863)
Open Market Disposition
-
Exchange Announcement
Meagher C.A., C.P.A., Patrick Joseph (CFO & Director)
Nov-26-2021
Common Shares
25,000
26,856
Private Acquisition
2,500.00
Multiple
Ross B.Comm, CGA, CPA, Christopher  (Former Chief Financial Officer)
Jul-30-2021
Common Shares
40,000
30,845
Derivative Exercise and Retained Stock
(100.00)
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Rogers, Hugh A. D.
President, CEO & Director
(604).650.6162
-

Meagher, Patrick Joseph
CFO & Director
780 818 6422
-

Lobenberg, Raimar 
Independent Director
780 818 6422
-

Probst, Wolfgang 
Director
780 818 6422
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Rogers, Hugh A. D.
President, CEO & Director
(604).650.6162
-

Meagher, Patrick Joseph
CFO & Director
780 818 6422
-

Beckert, Thomas 
Managing Director of XP Diagnostics GmbH & Vektor Pharma TF GmbH
780 818 6422
-

Jehle, Heinrich 
Head of Diagnostic Research
780 818 6422
-

Sahr, Florian A.
Head of Project Management
780 818 6422
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENTâS FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligenceâs opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
